Can men take semaglutide for weight loss?

What the trial data showed for male participants

The STEP 1 study (the pivotal phase 3 trial published in the New England Journal of Medicine) randomised 1,961 adults with obesity or overweight and at least one weight-related condition to 2.4mg semaglutide or placebo over 68 weeks. The trial population included men and women. At 68 weeks, participants on semaglutide achieved an average body-weight reduction of around 15%, compared with around 2.4% on placebo. Subgroup analyses consistently showed meaningful weight loss in men, though women tended to see slightly greater absolute percentage reductions on average, a pattern observed across several GLP-1 trials, thought to reflect differences in body composition, baseline metabolic rate, and starting muscle mass rather than any difference in how the medicine works.

That gap does not disqualify men from treatment. What it does mean is that a prescriber familiar with your starting weight, body composition goals, and any relevant health conditions is better placed to set realistic expectations than any generalised figure. The question our prescribers hear from men most often is not whether semaglutide works but how much and how quickly, both of which are genuinely individual.

For context on how semaglutide compares with other options, the semaglutide overview page covers the mechanism and licensed doses in detail.

Semaglutide's UK licence makes no distinction based on sex

Under its UK marketing authorisation, Wegovy is indicated for weight management alongside a reduced-calorie diet and increased physical activity in adults with a BMI of 30 or above, or a BMI of 27 to 29.9 with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea. The licence makes no sex-based restriction. The NHS medicines guidance for semaglutide reflects this: eligibility turns on BMI and clinical profile, not sex.

NICE's appraisal of semaglutide for weight management (TA875) similarly applies its criteria (comorbidities, BMI thresholds, and specialist-service requirements) without distinction between men and women. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, which the prescriber factors in at assessment.

If you are thinking about what treatment might suit your situation, the weight-loss treatment overview sets out the full range of licensed options currently available.

Practical and clinical considerations specific to men on semaglutide

A few things are worth knowing before starting. Men on GLP-1 treatment often begin with higher absolute body weight, which can mean slower percentage losses in early months, but also that the absolute kilograms lost are significant. Muscle preservation matters, and the clinical evidence base recommends combining treatment with resistance activity and adequate protein intake; your prescriber and the Patient Information Leaflet will give you specific guidance.

Side effects follow the same GI-led profile seen across all adults: nausea, loose stools, constipation, indigestion, and fatigue are the most commonly reported, typically most noticeable in the weeks after starting or after a dose increase before settling. The Wegovy cost page also covers what a private prescription includes beyond the medicine itself, which is worth reading if you are weighing up whether private treatment makes sense for your situation.

One thing that does not apply to men taking semaglutide (but is worth knowing if you share this page) is the contraception warning: the MHRA advises women of childbearing age to use effective contraception during treatment and for a period after stopping, because semaglutide is not recommended in pregnancy. That guidance is not relevant for male patients, but it is part of the broader prescribing picture. For anything specific to men's experience on this treatment, the men on Wegovy page goes into more detail.

How semaglutide is prescribed for men through a private service

Wegovy is a prescription-only medicine. The legal route to obtaining it (for men or anyone else) is a consultation with a qualified prescriber who assesses clinical suitability. At nume, that means a GPhC-registered Independent Prescriber reads your consultation personally, the same day you submit it. There is no algorithm making that call. Identity is verified, weight is confirmed on video, and if treatment is appropriate, the prescription is issued and the pen dispatched the same working day for free next-working-day tracked delivery.

If you are coming to this page because you are a man wondering whether semaglutide is even an option for you, the short answer is that your sex does not determine the answer. Your BMI, health history, and clinical profile do, and those are exactly what a prescriber is there to assess. More on men and Wegovy specifically is covered in a dedicated page if you want to go deeper before deciding. You can also review how and when the injection is used by reading about when to take semaglutide.

If you are ready to find out whether you are clinically suitable, a conversation with our prescribers is the right next step.